Is there still a need for specific central nervous system directed prophylaxis for diffuse large B-cell lymphoma in the rituximab era?

References

• Kumar A, Vanderplas A, LaCasce AS, et al. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer 2012;118:2944–2951.
   PubMed Web of Science ®Google Scholar
• Shimazu Y, Notohara K, Ueda Y. Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience. Int J Hematol 2009;89:577–583.
   PubMed Web of Science ®Google Scholar
• Boehme V, Schmitz N, Zeynalova S, et al. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2009;113:3896–3902.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Kuhnt E, Trumper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011;12:1013–1022.
   PubMed Web of Science ®Google Scholar
• Zhang J, Chen B, Xu X. Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis. Leuk Lymphoma 2014;55:509–514.
   PubMed Web of Science ®Google Scholar
• Chua SL, Seymour JF, Streater J, et al. Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma 2002;43:1783–1788.
   PubMed Web of Science ®Google Scholar
• Villa D, Connors JM, Shenkier TN, et al. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol 2010;21:1046–1052.
   PubMed Web of Science ®Google Scholar
• Tai WM, Chung J, Tang PL, et al. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. Ann Hematol 2011;90:809–818.
   PubMed Web of Science ®Google Scholar
• Tomita N, Yokoyama M, Yamamoto W, et al. Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 2012;103:245–251.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Assanelli A, Crocchiolo R, et al. Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic options. Hematol Oncol 2009;27:61–70.
   PubMed Web of Science ®Google Scholar
• Hollender A, Kvaloy S, Nome O, et al. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol 2002;13:1099–1107.
   PubMed Web of Science ®Google Scholar
• Murawski N, Zeynalova S, Held G, et al. Extralymphatic craniofacial diffuse large B-cell lymphoma: role of radiotherapy and intrathecal CNS prophylaxis. Hematol Oncol 2013;31(Suppl. 1): Abstract 48.
   Google Scholar
• Herbert K, Wolf M, Carney D, et al. The addition of systemic high-dose methotrexate (HD-MTX) to intrathecal chemotherapy (IT) for central nervous system (CNS) prophylaxis substantially reduces CNS recurrence rates in patients with at-risk aggressive lymphoma: a historically controlled prospective study. Blood 2008;112(Suppl. 1): Abstract 3596.
   Google Scholar
• Salzburg J, Burkhardt B, Zimmermann M, et al. Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report. J Clin Oncol 2007;25:3915–3922.
   PubMed Web of Science ®Google Scholar
• Siegal T, Goldschmidt N. CNS prophylaxis in diffuse large B-cell lymphoma: if, when, how and for whom?. Blood Rev 2012;26: 97–106.
   PubMed Web of Science ®Google Scholar
• Siegal T, Zylber-Katz E. Strategies for increasing drug delivery to the brain: focus on brain lymphoma. Clin Pharmacokinet 2002;41: 171–186.
   PubMed Web of Science ®Google Scholar
• Hryniuk WM, Bertino JR. Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlates. J Clin Invest 1969;48:2140–2155.
   PubMed Web of Science ®Google Scholar
• Tilly H, Lepage E, Coiffier B, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003; 102:4284–4289.
   PubMed Web of Science ®Google Scholar
• Abramson JS, Hellmann M, Barnes JA, et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer 2010;116:4283–4290.
   PubMed Web of Science ®Google Scholar
• Holte H, Leppä S, Björkholm M, et al. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Ann Oncol 2013;24:1385–1392.
   PubMed Web of Science ®Google Scholar
• Schmiegelow K. Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol 2009;146:489–503.
   PubMed Web of Science ®Google Scholar
• Blum R, Seymour JF, Toner G. Significant impairment of high-dose methotrexate clearance following vancomycin administration in the absence of overt renal impairment. Ann Oncol 2002; 13:327–330.
   PubMed Web of Science ®Google Scholar
• Brooks SL, Sanders J, Seymour JF, et al. A case of delayed methotrexate clearance following administration of a complementary medication containing chlorophyll. J Oncol Pharm Pract 2013 Jul 2. [Epub ahead of print]
   PubMedGoogle Scholar
• Bezabeh S, Mackey AC, Kluetz P, et al. Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors. Oncologist 2012;17:550–554.
   PubMed Web of Science ®Google Scholar